Treatment resistant schizophrenia: A comprehensive survey of randomised controlled trials

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Sinclair, Diarmid ^a   Adams, Clive E ^b  

^a SHEFFIELD HEALTH AND SOCIAL CARE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Randomised trials; Schizophrenia; Systematic reviews; Treatment resistant

Indexed keywords

AMINO ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; MOOD STABILIZER; NEUROLEPTIC AGENT; NOOTROPIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; OPIATE; RISPERIDONE;

ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ARTICLE; COGNITIVE THERAPY; ELECTROCONVULSIVE THERAPY; HUMAN; META ANALYSIS; PHYSIOTHERAPY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT FAILURE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITIVE THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84907278618     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0253-4     Document Type: Article

References (54)

1. Sartorius N, Shapiro R, Kimura M, Barrett K. WHO international pilot study of schizophrenia. Psychol Med 1972, 2(4):422-425. 10.1017/S0033291700045244, 4656537.
2. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001, 178:506-517. 10.1192/bjp.178.6.506, 11388966.
3. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997, 14(1):1-20. 10.1185/03007999709113338, 9524789.
4. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007, 10(1):23-41. 17417045.
5. Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res 2011, 133(1-3):54-62. 10.1016/j.schres.2011.09.016, 22000940.
6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45(9):789-796. 10.1001/archpsyc.1988.01800330013001, 3046553.
7. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997, 23(4):663-674. 10.1093/schbul/23.4.663, 9366002.
8. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-610. 10.1176/appi.ajp.163.4.600, 16585434.
9. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006, 32(4):715-723. 10.1093/schbul/sbj067, 16540702.
10. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012, 138(1):18-28. 10.1016/j.schres.2012.03.018, 22534420.
11. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012, 201(6):481-485. 10.1192/bjp.bp.111.105833, 22955007.
12. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992, 18(3):515-542. 10.1093/schbul/18.3.515, 1357741.
13. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JP. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004, 57(11):1124-1130. 10.1016/j.jclinepi.2004.02.018, 15612138.
14. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW, Murad MH, Sinclair D, Falck-Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011, 64(12):1283-1293. 10.1016/j.jclinepi.2011.01.012, 21839614.
15. Adams CE, Davis J, Duggan L, Essali A, Fenton M, Leucht S, Jayaram M, Li C, Tharyan P, Välimäki M. About the Cochrane collaboration (Cochrane Review Groups (CRGs). 2013, :. Issue 8. Art. No.: SCHI.
16. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 2012, 4:CD008712. 22513966.
17. Pharoah F, Mari Jair J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010, (12):Art. No.: CD000088. doi:10.1002/14651858.CD000088.pub3.
18. Rathbone J, Xia J. Acupuncture for schizophrenia. Cochrane Database Syst Rev 2005, (4):Art. No.: CD005475. doi:10.1002/14651858.CD005475.
19. Tharyan P, Adams Clive E. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005, (2):Art. No.: CD000076. doi:10.1002/14651858.CD000076.pub2.
20. Dougall N, McIntosh A, Ebmeier Klaus P. Transcranial magnetic stimulation for schizophrenia. Cochrane Database Syst Rev 2006, (3):Art. No.: CD006081. doi:10.1002/14651858.CD006081.
21. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009, (3):Art. No.: CD006324. doi:10.1002/14651858.CD006324.pub2.
22. Wang J, Omori Ichiro M, Fenton M, Soares Bernardo GO. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010, (1):Art. No.: CD008125. doi:10.1002/14651858.CD008125.pub2.
23. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008, (3):Art. No.: CD004028. doi:10.1002/14651858.CD004028.pub3.
24. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006, (4):CD005962. doi:10.1002/14651858.CD005962.pub2.
25. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007, (3):CD003834. doi:10.1002/14651858.CD003834.pub2.
26. Kour K, Kaur R, Singh J. Memantine for schizophrenia. Cochrane Database Syst Rev 2013, (6):Art. No.: CD010552. doi:10.1002/14651858.CD010552.
27. Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006, (2):Art. No.: CD003730. doi:10.1002/14651858.CD003730.pub2.
28. Leucht S, Helfer B, Dold M, Kissling W, McGrath J. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2014, (5):Art. No.: CD001258. doi:10.1002/14651858.CD001258.pub3.
29. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto Joaquim I, Kissling W, Leucht S. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010, (1):Art. No.: CD006624. doi:10.1002/14651858.CD00624.pub2.
30. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh Hany G, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2014, (1):Art. No.: CD006569. doi:10.1002/14651858.CD006569.pub5.
31. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009, (1):Art. No.: CD000059. doi:10.1002/14651858.CD000059.pub2.
32. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010, (11):Art. No.: CD006633. doi:10.1002/14651858.CD006633.pub2.
33. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010, (3):Art. No.: CD006654. doi:10.1002/14651858.CD006654.pub2.
34. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev 2009, (4):Art. No.: CD007474. doi:10.1002/14651858.CD007474.pub2.
35. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2011, (1):Art. No.: CD006626. doi:10.1002/14651858.CD006626.pub2.
36. Hunter R, Kennedy E, Song F, Gadon L, Irving Claire B. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003, (2):Art. No.: CD000440. doi:10.1002/14651858.CD000440.
37. Asmal L, Flegar Srnka J, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013, (11):Art. No.: CD006625. doi:10.1002/14651858.CD006625.pub3.
38. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmid F, Lewis R, Kissling W, Leucht S. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009, (42):Art. No.: CD006752. doi:10.1002/14651858.CD006752.pub2.
39. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi Paranthaman S, Kissling W, Leucht S. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009, (4):Art. No.: CD006627. doi:10.1002/14651858.CD006627.pub2.
40. Saha Kumar B, Sampson S, Zaman Rashid U. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2013, (2):Art. No.: CD010631. doi:10.1002/14651858.CD010631.
41. Sampford J, Sampson S. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013, (11):Art. No.: CD010832. doi:10.1002/14651858.CD010832.
42. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2011, (8):Art. No.: CD009230. doi:10.1002/14651858.CD009230.pub2.
43. Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database Syst Rev 2012, (5):Art. No.: CD009831. doi:10.1002/14651858.CD009831.
44. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissling W. Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2011, (10):Art. No.: CD009369. doi:10.1002/14651858.CD009369.
45. Lloyd K, White J. Democratizing clinical research. Nature 2011, 474(7351):277-278. 10.1038/474277a, 21677725.
46. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 2012, 125(1):15-24. 10.1111/j.1600-0447.2011.01792.x, 22077319.
47. Faries DA-SH, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26. 10.1186/1471-244X-5-26, 15921508.
48. Stahl SM. Emerging guidelines for the use of antipsychotic polypharmacy. Revista de psiquiatria y salud mental 2013, 6(3):97-100. 23485567.
49. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 2014. Available at www.nice.org.uk/CG178 [NICE guideline]., www.nice.org.uk/CG178
50. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(2):1-56. 15000267.
51. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135(11):982-989. 10.7326/0003-4819-135-11-200112040-00010, 11730399.
52. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994, 272(2):122-124. 10.1001/jama.1994.03520020048013, 8015121.
53. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962, 10:790-812.
54. Leucht S, Kane JM, Kissling W, Hamann J, Etschel EVA, Engel R. Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry 2005, 187(4):366-371. 10.1192/bjp.187.4.366, 16199797.